
Gossamer Bio, Inc.
Gossamer Bio, Inc.(GOSS)股东结构
基于 13F 申报与流通股数据,展示机构、内部人与公众持股结构;下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · GOSS · 截至 2025年9月30日
股东结构概览
179
机构持有人数
▲ 45 vs Q2
$473.65M
机构持仓总市值
▲ $255.65M vs Q2
234.70M
总流通股
freeFloat 83.14%
180.10M
13F 申报持股数
▲ 2.86M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源:FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
GOSS 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
NEA MANAGEMENT COMPANY, LLC pharmaceutical preparations | 18.09M | 7.96% | 7.96% | $47.58B | Nov 14, 2025 | — held |
OCTAGON CAPITAL ADVISORS LP pharmaceutical preparations | 17.05M | 7.50% | 7.50% | $44.84B | Nov 14, 2025 | ▼ 1.30M |
BLACKROCK, INC. pharmaceutical preparations | 13.85M | 6.09% | 6.09% | $36.42B | Nov 12, 2025 | ▲ 1.70M |
VANGUARD GROUP INC pharmaceutical preparations | 12.01M | 5.28% | 5.28% | $31.59B | Nov 7, 2025 | ▲ 599.0K |
ARCH VENTURE MANAGEMENT, LLC pharmaceutical preparations | 8.06M | 3.54% | 3.54% | $21.19B | Nov 14, 2025 | — held |
SAMSARA BIOCAPITAL, LLC pharmaceutical preparations | 6.13M | 2.70% | 2.70% | $16.12B | Nov 14, 2025 | — held |
PALO ALTO INVESTORS LP pharmaceutical preparations | 5.46M | 2.40% | 2.40% | $14.37B | Nov 14, 2025 | ▼ 274.7K |
SIREN, L.L.C. pharmaceutical preparations | 5.21M | 2.29% | 2.29% | $13.70B | Nov 13, 2025 | — held |
683 CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 5.06M | 2.23% | 2.23% | $13.31B | Nov 14, 2025 | ▼ 1.28M |
ACADIAN ASSET MANAGEMENT LLC pharmaceutical preparations | 5.01M | 2.21% | 2.21% | $13.18B | Nov 13, 2025 | ▼ 2.13M |
数据来源:SEC 13F 申报文件。变动标识:isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
21
增持
+23.89M 股7
新建仓
首次建仓15
减持
−17.26M 股0
清仓
完全退出净股数变化(前50家)
+6.63M
+23.89M / −17.26M
净新增持仓人
+13
新建 7 个 / 退出 0 个
基于前50家最大机构持仓统计,全市场实际数量可能不同。
内幕交易买卖情绪
GOSS 内幕交易记录
数据来源:SEC Form 4
6
买入笔数
0
卖出笔数
0.00
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
Quisel John D director | Jun 4, 2026 | Award | 115,000 | $0.18 | $20.5K | 115.0K | Form 4 ↗ |
Drynan Skye director | Jun 4, 2026 | Award | 115,000 | $0.18 | $20.5K | 115.0K | Form 4 ↗ |
Daniel Thomas O director | Jun 4, 2026 | Award | 115,000 | $0.18 | $20.5K | 115.0K | Form 4 ↗ |
Cox Russell J. director | Jun 4, 2026 | Award | 115,000 | $0.18 | $20.5K | 115.0K | Form 4 ↗ |
Milligan Sandra director | Jun 4, 2026 | Award | 115,000 | $0.18 | $20.5K | 115.0K | Form 4 ↗ |
Nathan Steven D director | Jun 4, 2026 | Award | 115,000 | $0.18 | $20.5K | 115.0K | Form 4 ↗ |
Aranda Richard Chief Medical Officer | Mar 19, 2026 | Award | 572,000 | $0.45 | $257.4K | 572.0K | Form 4 ↗ |
Aranda Richard Chief Medical Officer | Mar 19, 2026 | Award | 562,500 | $0.45 | $253.1K | 562.5K | Form 4 ↗ |
Aranda Richard Chief Medical Officer | Mar 19, 2026 | Award | 487,500 | $0.45 | $219.4K | 487.5K | Form 4 ↗ |
Aranda Richard Chief Medical Officer | Mar 19, 2026 | Award | 162,500 | $0.45 | $73.1K | 162.5K | Form 4 ↗ |
数据来源:SEC Form 4。买卖方向:acquisitionOrDisposition A=买入,D=卖出。已排除 RSU 归属(M-Exempt)。
关于机构与内部人持股结构
Gossamer Bio, Inc.(GOSS)主要由机构投资者持有,机构持股比例约为 76.7%。公司内部人员持股约 16.86%,散户及公众持股约占剩余的 6.40%。
Gossamer Bio, Inc. 最大机构股东为 NEA MANAGEMENT COMPANY, LLC,截至 September 30, 2025 持有约 18.09 million 股,占总流通股的 7.96%。
目前共有 179 家机构持有 GOSS 股票,合计持仓市值约 $473,654,631,数据来源为最新 SEC 13F 申报。
常见问题
GOSS ownershipGossamer Bio, Inc.(GOSS)主要由机构投资者持有,机构持股约 76.7%。最大股东为 NEA MANAGEMENT COMPANY, LLC,持股比例 7.96%。内部人员持股约 16.86%。数据来源 SEC Form 13F,截至 September 30, 2025。